Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 3988-3995

  Marquez, Bernadette V ^a   Ikotun, Oluwatayo F ^a   Zheleznyak, Alexander ^a   Wright, Brian ^a   Hari Raj, Amrita ^a   Pierce, Richard A ^b   Lapi, Suzanne E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

89Zr; Breast cancer xenograft; HER2; NOG; Pertuzumab; PET; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB ZR 89; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; CARRIER PROTEIN; MONOCLONAL ANTIBODY; NOGGIN PROTEIN; PERTUZUMAB; RADIOPHARMACEUTICAL AGENT; ZIRCONIUM;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BREAST CANCER; BT 474 CELL LINE; CANCER CELL LINE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SCREENING; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THIN LAYER CHROMATOGRAPHY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME IMMUNOASSAY; EVALUATION STUDY; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR IMAGING; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCID MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, SCID; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIRCONIUM;

EID: 84942881621     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500323d     Document Type: Article

References (29)

1. 89Zr-bevacizumab PET imaging in primary breast cancer. J. Nucl. Med. 2013, 54, 1014-1018.
2. 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. J. Urol. 2013, 1439-1445.
3. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87, 586-592.
4. Capelan, M.; Pugliano, L.; De Azambuja, E. Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals Oncol. 2013, 273-282.
5. Tamura, K.; Kurihara, H.; Yonemori, K.; et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J. Nucl. Med. 2013, 54, 1869-1875.
6. Imaging With 111 Indium (111In)-pertuzumab (PmAb) to Predict Response to trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) (PETRA): Ontario Clinical Oncology Group, 2013. ClinicalTrials.gov (accessed June 2014).
7. McLarty, K.; Cornelissen, B.; Cai, Z.; et al. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J. Nucl. Med. 2009, 50, 1340-1348.
8. Persson, M.; Gedda, L.; Lundqvist, H.; et al. [177Lu]pertuzumab: Experimental Therapy of HER-2-Expressing Xenografts. Cancer Res. 2007, 67, 326-331.
9. Scheuer, W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; Endl, J.; Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69, 9330-9336.
10. Fuentes, G.; Scaltriti, M.; Baselga, J.; Verma, C. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res. 2011, 13, R54.
11. 89Zr Using an Automated Module. Appl. Sci. 2013, 3, 593-613.
12. 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 2003, 44, 1271-1281.
13. Holland, J. P.; Sheh, Y.; Lewis, J. S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 2009, 36, 729-739.
14. Perk, L. R.; Vosjan, M. J.; Visser, G. W.; et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 250-259.
15. Vosjan, M. J.; Perk, L. R.; Visser, G. W.; et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine. Nat. Protoc. 2010, 5, 739-743.
16. Ikotun, O. F.; Marquez, B. V.; Huang, C.; et al. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET. PLoS One 2013, 8, e77476.
17. Zhang, H.; Cui, W.; Gross, M. L. Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies. FEBS Lett. 2014, 588, 308-317.
18. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 1984, 72, 77-89.
19. Lub-de Hooge, M. N.; Kosterink, J. G. W.; Perik, P. J.; et al. Preclinical characterisation of In-111-DTPA-trastuzumab. Br. J. Pharmacol. 2004, 143, 99-106.
20. 89Zr-Radiolabeled trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals (Basel) 2012, 5, 79-93.
21. Nanni, P.; Nicoletti, G.; Palladini, A.; et al. Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2-/-;Il2rg-/Mice and Treatment with PI3K Inhibitor. PLoS One 2012, 7, e39626.
22. Box, G. E. P.; Hunter, W. G.; Hunter, J. S. 7.8 Simplification and Increased Sensitivity from Transformation. Statistics for Experimenters: An Introduction to Design, Data Analysis, and Model Building; John Wiley and Sons, Inc: Canada, 1978; pp 231-238.
23. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P. A., Jr Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 1984, 72, 77-89.
24. Pegram, M. D.; Konecny, G. E.; O'Callaghan, C.; Beryt, M.; Pietras, R.; Slamon, D. J. Rational Combinations of trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. J. Natl. Cancer Inst. 2004, 96, 739-749.
25. Moldoveanu, Z.; Epps, J. M.; Thorpe, S. R.; Mestecky, J. The sites of catabolism of murine monomeric IgA. J. Immunol. 1988, 141, 208-213.
26. Henderson, L. A.; Baynes, J. W.; Thorpe, S. R. Identification of the sites of IgG catabolism in the rat. Arch. Biochem. Biophys. 1982, 215, 1-11.
27. Ferl, G. Z.; Kenanova, V.; Wu, A. M.; DiStefano, J. J., 3rd A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol. Cancer Ther. 2006, 5, 1550-1558.
28. 89Zr PET Imaging of Hepatocellular Carcinoma. J. Nucl. Med. 2014, 13, 13.
29. 89Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer. PLoS One 2013, 8, e61230.